Skeletal muscle atrophy and sarcopenia have become one of the biggest non-communicable diseases and threaten human health. Skeletal muscle atrophy and sarcopenia occur due to many different stimuli, including obesity, aging, denervation, bed rest, sepsis, metabolic diseases, and cancer. Meanwhile, muscle atrophy's loss of strength and endurance limits activity impairs quality of life, leads to falls and fractures, and can create a vicious cycle of muscle disuse and further muscle loss and weakness. The main factors significantly modulating the balance between protein biogenesis/biosynthesis versus removal/destruction are mechanical, oxidative, nutritional, and energy stresses and growth factors or cytokines. The management of skeletal muscle atrophy and sarcopenia is a complex and multifaceted process including drug therapy and lifestyle interventions. Evidence from various preclinical and clinical studies has revealed that various dietary components (nutrients, phytochemicals, prebiotics/probiotics, etc.) play a significant role in maintaining muscle health and emerge as potential therapeutic agents in a broad range of skeletal muscle atrophy and sarcopenia models.
This Research Topic aims to update the understanding of the molecular mechanisms that mediate and orchestrate the loss of muscle mass in disease and to provide the current contemporary knowledge of the effects of dietary components (nutrients, phytochemicals, prebiotics/probiotics, etc.) on skeletal muscle atrophy and sarcopenia, including obese sarcopenia, with an ultimate aim to offer new insights into potential preventive or therapeutic approaches (dietary and pharmacological intervention) for the clinical management of skeletal muscle atrophy and sarcopenia.
We invite original research papers and reviews related to nutrition in skeletal muscle atrophy and sarcopenia, including obese sarcopenic state, focusing on, but not limited to:
· The preclinical and clinical studies investigating the effect of dietary components, especially phytochemicals and probiotics, on disease-induced skeletal muscle atrophy and sarcopenia;
· Identification of novel and emerging pathways or molecules that control skeletal muscle loss;
· The effect of intermuscular or intramuscular fat on skeletal muscle atrophy and sarcopenia;
· The effect of physical activity on skeletal muscle atrophy and sarcopenia;
· The role of the gut microbiome and metabolites on skeletal muscle mass.
Skeletal muscle atrophy and sarcopenia have become one of the biggest non-communicable diseases and threaten human health. Skeletal muscle atrophy and sarcopenia occur due to many different stimuli, including obesity, aging, denervation, bed rest, sepsis, metabolic diseases, and cancer. Meanwhile, muscle atrophy's loss of strength and endurance limits activity impairs quality of life, leads to falls and fractures, and can create a vicious cycle of muscle disuse and further muscle loss and weakness. The main factors significantly modulating the balance between protein biogenesis/biosynthesis versus removal/destruction are mechanical, oxidative, nutritional, and energy stresses and growth factors or cytokines. The management of skeletal muscle atrophy and sarcopenia is a complex and multifaceted process including drug therapy and lifestyle interventions. Evidence from various preclinical and clinical studies has revealed that various dietary components (nutrients, phytochemicals, prebiotics/probiotics, etc.) play a significant role in maintaining muscle health and emerge as potential therapeutic agents in a broad range of skeletal muscle atrophy and sarcopenia models.
This Research Topic aims to update the understanding of the molecular mechanisms that mediate and orchestrate the loss of muscle mass in disease and to provide the current contemporary knowledge of the effects of dietary components (nutrients, phytochemicals, prebiotics/probiotics, etc.) on skeletal muscle atrophy and sarcopenia, including obese sarcopenia, with an ultimate aim to offer new insights into potential preventive or therapeutic approaches (dietary and pharmacological intervention) for the clinical management of skeletal muscle atrophy and sarcopenia.
We invite original research papers and reviews related to nutrition in skeletal muscle atrophy and sarcopenia, including obese sarcopenic state, focusing on, but not limited to:
· The preclinical and clinical studies investigating the effect of dietary components, especially phytochemicals and probiotics, on disease-induced skeletal muscle atrophy and sarcopenia;
· Identification of novel and emerging pathways or molecules that control skeletal muscle loss;
· The effect of intermuscular or intramuscular fat on skeletal muscle atrophy and sarcopenia;
· The effect of physical activity on skeletal muscle atrophy and sarcopenia;
· The role of the gut microbiome and metabolites on skeletal muscle mass.
